Prevention & lipidsSecondary analysis
Impact of Bempedoic Acid on Total Cardiovascular Events
- Secondary analysis of the CLEAR Outcomes randomised trial
- prespecified analysis
Authors' conclusion
Lowering LDL-C level with bempedoic acid reduced the total number of cardiovascular events in patients with high cardiovascular risk, statin therapy intolerance, and elevated LDL-C levels.
Study context
- Population
- Patients with, or at high risk for, CVD, with hypercholesterolemia and inability to take guideline-recommended statins
- Participants
- 13,970 participants
- Comparison
- Bempedoic acid vs placebo
- Primary endpoint
- Total (first and additional) MACE-4 events (CV death, nonfatal MI, nonfatal stroke or coronary revascularization)
- Follow-up
- Median 3.4 years
Primary result
Total MACE-4
Hazard ratio
0.80
95% CI 0.72–0.89
P < 0.001
Bempedoic acid vs Placebo
HR 0.80 (95% CI 0.72–0.89); P < 0.001
As reported in the abstract
Secondary outcomes
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Total MACE-3, MI, coronary revascularization, stroke — Bempedoic acid vs Placebo · MACE-3 | 0.83 (0.73–0.93) | P = 0.002 | |
| Total MACE-3, MI, coronary revascularization, stroke — Bempedoic acid vs Placebo · MI | 0.69 (0.58–0.83) | P < 0.001 | |
| Total MACE-3, MI, coronary revascularization, stroke — Bempedoic acid vs Placebo · coronary revascularization | 0.78 (0.68–0.89) | P < 0.001 | |
| Total MACE-3, MI, coronary revascularization, stroke — Bempedoic acid vs Placebo · stroke, not statistically significant | 0.80 (0.63–1.03) | ||
| 0.512Hazard ratio (log scale) |
Low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hsCRP) with bempedoic acid · 6 months
- LDL-C reduction
- 21%
- hsCRP reduction
- 22%
Original publication
Impact of Bempedoic Acid on Total Cardiovascular Events. JAMA Cardiol. Published 1 March 2024. doi:10.1001/jamacardio.2023.5155
Summarised from the published abstract; every number is checked against it